Skip to main content
OpenTrials
Completed

NCT Number: NCT00819403

Simvastatin With or Without Ezetimibe and Atherothrombotic Biomarker Assessment

To determine whether the combination of ezetimibe and simvastatin improves biomarkers of atherothrombosis compared to simvastatin alone in patients with the metabolic syndrome.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Johns Hopkins Hospital, Baltimore, Maryland, United States

Loading trial locations.

About this study

  • To assess the ex vivo effects of ezetimibe/simvastatin (E/S) (Vytorin 10/40mg) and simvastatin (S) (Zocor 40mg) on platelet and inflammation biomarkers in patients with documented metabolic syndrome.
  • To compare platelet-related effects including PAR-1 receptor inhibition of E/S with those of the established anti-platelet agents including aspirin, clopidogrel, intravenous and oral glycoprotein IIb/IIIa inhibitors.
  • To determine whether the addition of ezetimibe will yield extra protection beyond lipid modulation in the reduction of inflammation and platelet activation.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women greater than or equal to 21 years of age
  • Diagnosis of metabolic syndrome. We defined the presence of metabolic syndrome based on the US National Cholesterol Education Program's Adult Treatment Panel III guidelines. Specifically, metabolic syndrome will be diagnosed and documented when 3 of the following 5 characteristics will be present:
  • abdominal obesity, given as waist circumference for men > 102 cm, and for women > 88 cm
  • triglycerides > 150 mg/dL
  • HDL cholesterol < 40 mg/dL for men, and < 50 mg/dL for women
  • blood pressure > 130/85 mm Hg
  • fasting glucose > 100 mg/dL

Exclusion criteria

  • Patients will be excluded for a history of bleeding diathesis
  • drug or alcohol abuse
  • prothrombin time greater than 1.5 times control
  • platelet count < 100,000/mm3
  • hematocrit < 25%
  • creatinine > 4.0 mg/dl
  • surgery or angioplasty performed within 3 months or planned for the future
  • history of gastrointestinal or other bleeding
  • history of drug-induced disorders
  • trauma, cancer, rheumatic diseases, coronary artery disease or stroke
  • Patients participating in other investigational drug trials within one month of completion will be also excluded
  • Patients treated with intravenous platelet glycoprotein IIb/IIIa inhibitors or thienopyridines, within past 6 months
  • Patients treated with statins or aspirin within past four weeks

Treatment and study plan

simvastatin

Drug

Subjects will receive 6 weeks of simvastatin 40 mg, after which atherothrombotic biomarker assessment will be studied.

Other names: zocor

ezetimibe/simvastatin

Drug

Subjects will receive 6 weeks of ezetimibe/simvastatin 10/40 mg, after which atherothrombotic biomarker assessment will be studied.

Other names: vytorin

Primary outcomes

  1. Ex Vivo Effects of Treatment With Vytorin Versus Zocor for 6 Weeks on Platelet Alpha Thrombin PAR-1 Receptor Expression

    Time frame: 6 weeks

    Measured using whole blood flow cytometry

Secondary outcomes

  1. Biomarkers of Inflammation

    Time frame: 6 weeks

Sponsors and collaborators

Lead sponsor

University of Maryland, Baltimore

Other

Collaborators

  • Merck Sharp & Dohme LLC

Registry information

Official study title

The Effects of Ezetimibe/Simvastatin Versus Simvastatin Alone on Platelet and Inflammatory Biomarkers in Patients With the Metabolic Syndrome

Important dates

Study start
2009
Primary completion
2011
Study completion
2011
First posted
Jan 9, 2009
Registry last updated
Jan 14, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.